PMV Pharmaceuticals (PMV Pharmaceuticals) Scaled Net Operating Assets : 0.14 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is PMV Pharmaceuticals Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

PMV Pharmaceuticals's operating assets for the quarter that ended in Dec. 2023 was $49.10 Mil. PMV Pharmaceuticals's operating liabilities for the quarter that ended in Dec. 2023 was $13.18 Mil. PMV Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2023 was $261.03 Mil. Therefore, PMV Pharmaceuticals's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was 0.14.

PMV Pharmaceuticals Scaled Net Operating Assets Historical Data

The historical data trend for PMV Pharmaceuticals's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PMV Pharmaceuticals Scaled Net Operating Assets Chart

PMV Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Scaled Net Operating Assets

Get a 7-Day Free Trial

-2.71

-0.02

0.06

0.13

PMV Pharmaceuticals Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Scaled Net Operating Assets	Get a 7-Day Free Trial															0.07	0.05	0.17	0.20	0.14

Competitive Comparison of PMV Pharmaceuticals's Scaled Net Operating Assets

For the Biotechnology subindustry, PMV Pharmaceuticals's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PMV Pharmaceuticals's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PMV Pharmaceuticals's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where PMV Pharmaceuticals's Scaled Net Operating Assets falls into.

PMV Pharmaceuticals Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

PMV Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2023 )
=	(Operating Assets (A: Dec. 2023 )	-	Operating Liabilities (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2022 )
=	(49.095	-	13.177)	/	270.308
=	0.13

where

	Operating Assets		(A: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	252.152	-	203.057
=	49.095

	Operating Liabilities		(A: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	26.463	-	12.434	-	0.852
=	13.177

PMV Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Dec. 2023 )
=	(Operating Assets (Q: Dec. 2023 )	-	Operating Liabilities (Q: Dec. 2023 ))	/	Total Assets (Q: Sep. 2023 )
=	(49.095	-	13.177)	/	261.027
=	0.14

where

	Operating Assets		(Q: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	252.152	-	203.057
=	49.095

	Operating Liabilities		(Q: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	26.463	-	12.434	-	0.852
=	13.177

PMV Pharmaceuticals Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of PMV Pharmaceuticals's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

PMV Pharmaceuticals (PMV Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PMV Pharmaceuticals Inc (NAS:PMVP) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Research Way, Princeton, NJ, USA, 08536

Website

https://www.pmvpharma.com

PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.

Executives

Orbimed Advisors Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Leila Alland	officer: Chief Medical Officer	C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
Deepika Jalota	officer: SVP, Regulatory Affairs and QA	C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
Carol Giltner Gallagher	director	C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Orbimed Capital Gp V Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Kirsten Flowers	director	C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Thilo Schroeder	director, 10 percent owner	C/O NEXTECH INVEST LTD., BAHNHOFSTRASSE 18, ZURICH V8 8001
Arnold J Levine	director	C/O JAN STERN REED BAXTER INTERNATIONAL, ONE BAXTER PARKWAY DF2 2W, DEERFIELD IL 60015
Winston Kung	officer: COO, CFO	C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
David Henry Mack	director, officer: President and CEO	ONE EMBARCADERO CENTER, SUITE 3700, SAN FRANCISCO CA 94111
Euclidean Capital Llc	10 percent owner	160 FIFTH AVE, 9TH FL, NEW YORK NY 10010
James H Simons	10 percent owner	RENAISSANCE TECHNOLOGIES LLC, 800 THIRD AVE, NEW YORK NY 10022
Greenland A Llc	10 percent owner	C/O EUCLIDEAN CAPITAL LLC, 160 FIFTH AVE, 9TH FL, NEW YORK NY 10010